In 2005, loss of LLGL1 was associated with tumor-suppressive functions and was then linked with metastatic colorectal cancer, melanoma, endometrial cancer, hepatocellular cancer, pancreatic cancer, glioma, and lung cancer [30–36]. Here, LLGL1 is linked to endometrial cancer.